Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)’s share price dropped 4% on Monday . The stock traded as low as $30.80 and last traded at $30.80, with a volume of 715,845 shares trading hands. The stock had previously closed at $32.10.

ALDR has been the topic of several recent analyst reports. Zacks Investment Research upgraded Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 30th. Jefferies Group reiterated a “buy” rating on shares of Alder BioPharmaceuticals in a report on Thursday, June 30th. Brean Capital reissued a “positive” rating and issued a $45.00 target price on shares of Alder BioPharmaceuticals in a research report on Wednesday, July 27th. Finally, Wells Fargo & Co. initiated coverage on Alder BioPharmaceuticals in a research report on Thursday, April 21st. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Alder BioPharmaceuticals presently has an average rating of “Buy” and a consensus target price of $47.60.

The stock’s market cap is $1.54 billion. The stock’s 50 day moving average price is $26.90 and its 200 day moving average price is $25.21.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings results on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.04. The firm earned $0.11 million during the quarter, compared to the consensus estimate of $1.14 million. The company’s revenue for the quarter was up 112900.0% on a year-over-year basis. During the same period last year, the firm posted ($0.46) earnings per share. On average, equities research analysts expect that Alder BioPharmaceuticals Inc. will post ($2.76) earnings per share for the current year.

In related news, CEO Randall C. Schatzman sold 10,000 shares of the company’s stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $28.02, for a total transaction of $280,200.00. Following the sale, the chief executive officer now owns 115,933 shares in the company, valued at approximately $3,248,442.66. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mark James Litton sold 25,000 shares of the company’s stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $30.05, for a total value of $751,250.00. Following the sale, the insider now owns 79,847 shares in the company, valued at approximately $2,399,402.35. The disclosure for this sale can be found here.

Other large investors have made changes to their positions in the company. Nationwide Fund Advisors raised its stake in shares of Alder BioPharmaceuticals by 103.6% in the fourth quarter. Nationwide Fund Advisors now owns 30,380 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 15,457 shares during the last quarter. Pyrrho Capital Management LP raised its stake in shares of Alder BioPharmaceuticals by 205.0% in the fourth quarter. Pyrrho Capital Management LP now owns 63,000 shares of the biopharmaceutical company’s stock valued at $2,081,000 after buying an additional 42,343 shares during the last quarter. California Public Employees Retirement System raised its stake in shares of Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock valued at $2,685,000 after buying an additional 72,600 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock valued at $8,911,000 after buying an additional 200,707 shares during the last quarter. Finally, Janus Capital Management raised its stake in shares of Alder BioPharmaceuticals by 391.1% in the third quarter. Janus Capital Management now owns 4,239,855 shares of the biopharmaceutical company’s stock valued at $138,900,000 after buying an additional 3,376,540 shares during the last quarter.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.